Hospital de Cruces-ko ikertzaileekin lankidetzan egindako argitalpenak (4)

2021

  1. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

    The Lancet, Vol. 398, Núm. 10295, pp. 121-130

2017

  1. Prognostic models for locally advanced cervical cancer: External validation of the published models

    Journal of Gynecologic Oncology, Vol. 28, Núm. 5

2014

  1. Bladder cancer index: Cross-cultural adaptation into Spanish and psychometric evaluation

    Health and Quality of Life Outcomes, Vol. 12, Núm. 1

2007

  1. Previous tumour as a prognostic factor in stage I non-small cell lung cancer

    Thorax, Vol. 62, Núm. 5, pp. 386-390